Literature DB >> 9491498

Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime.

T Hanke1, T J Blanchard, J Schneider, C M Hannan, M Becker, S C Gilbert, A V Hill, G L Smith, A McMichael.   

Abstract

Human immunodeficiency virus (HIV) vaccine candidates were previously constructed as a string of cytotoxic T lymphocyte (CTL) epitopes delivered and expressed using DNA and modified virus Ankara (MVA; an attenuated vaccinia virus) vectors. These vaccines were shown to induce interferon (IFN)-gamma-producing and cytolytic CD8+ T cells after a single vaccine administration. In the course of this work, immunization protocols were sought which would improve the levels of induced HIV-specific T cells. It was found that previous immunological exposure to MVA reduced the efficiency of subsequent priming and boosting using the same vaccine vehicle. However, a combined regime whereby the animals were first primed with the DNA vaccine and then boosted with MVA was the most potent protocol for the induction of both interferon-gamma-producing and cytolytic T cells against two CTL epitopes simultaneously. The general applicability of this novel vaccination method for induction of major histocompatibility complex class I-restricted T cells is discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9491498     DOI: 10.1016/s0264-410x(97)00226-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  50 in total

Review 1.  Immunotherapy of melanoma.

Authors:  C Smith; V Cerundolo
Journal:  Immunology       Date:  2001-09       Impact factor: 7.397

Review 2.  Evaluation of events occurring at mucosal surfaces: techniques used to collect and analyze mucosal secretions and cells.

Authors:  Bruno Guy
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

3.  Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to that with conventional plasmid DNA vaccine.

Authors:  Maria L Knudsen; Alice Mbewe-Mvula; Maximillian Rosario; Daniel X Johansson; Maria Kakoulidou; Anne Bridgeman; Arturo Reyes-Sandoval; Alfredo Nicosia; Karl Ljungberg; Tomás Hanke; Peter Liljeström
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

Review 4.  Poly-N-acetyl glucosamine gel matrix as a non-viral delivery vector for DNA-based vaccination.

Authors:  Mohamed L Salem; Marina Demcheva; William E Gillanders; David J Cole; John N Vournakis
Journal:  Anticancer Res       Date:  2010-10       Impact factor: 2.480

5.  Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa.

Authors:  Igor M Belyakov; Vladimir A Kuznetsov; Brian Kelsall; Dennis Klinman; Marcin Moniuszko; Michael Lemon; Phillip D Markham; Ranajit Pal; John D Clements; Mark G Lewis; Warren Strober; Genoveffa Franchini; Jay A Berzofsky
Journal:  Blood       Date:  2005-12-22       Impact factor: 22.113

6.  Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization.

Authors:  Toshio Naito; Yutaro Kaneko; Danuta Kozbor
Journal:  J Gen Virol       Date:  2007-01       Impact factor: 3.891

7.  Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection.

Authors:  Todd M Allen; Peicheng Jing; Briana Calore; Helen Horton; David H O'Connor; Tomas Hanke; Marian Piekarczyk; Richard Ruddersdorf; Bianca R Mothé; Carol Emerson; Nancy Wilson; Jeffrey D Lifson; Igor M Belyakov; Jay A Berzofsky; Chenxi Wang; David B Allison; David C Montefiori; Ronald C Desrosiers; Steven Wolinsky; Kevin J Kunstman; John D Altman; Alessandro Sette; Andrew J McMichael; David I Watkins
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Sustained peptide-specific gamma interferon T-cell response in rhesus macaques immunized with human immunodeficiency virus gag DNA vaccines.

Authors:  Michael J Caulfield; Su Wang; Jeffrey G Smith; Timothy W Tobery; Xu Liu; Mary-Ellen Davies; Danilo R Casimiro; Tong-Ming Fu; Adam Simon; Robert K Evans; Emilio A Emini; John Shiver
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines.

Authors:  Linda S Wyatt; Patricia L Earl; Jennifer Vogt; Leigh Anne Eller; Dev Chandran; Jinyan Liu; Harriet L Robinson; Bernard Moss
Journal:  Vaccine       Date:  2007-12-03       Impact factor: 3.641

10.  Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA).

Authors:  Rachael Chiam; Emma Sharp; Sushila Maan; Shujing Rao; Peter Mertens; Barbara Blacklaws; Nick Davis-Poynter; James Wood; Javier Castillo-Olivares
Journal:  PLoS One       Date:  2009-06-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.